Galimedix Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Galimedix Therapeutics sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Galimedix Therapeutics: 1 sponsored US clinical trial, 1 recruiting.

Galimedix Therapeutics sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Geographic Atrophy of the Macula, with 1 trials.

Mid-pack sponsor footprint

Galimedix Therapeutics is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Galimedix Therapeutics pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Geographic Atrophy of the Macula (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Galimedix Therapeutics: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Galimedix Therapeutics sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Galimedix Therapeutics1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Galimedix Therapeutics sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Galimedix Therapeutics sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Galimedix Therapeutics page

1 registered trials is a research-attention snapshot, not an endorsement of Galimedix Therapeutics or any single study.

  • 1 of Galimedix Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Geographic Atrophy of the Macula is the condition Galimedix Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Geographic Atrophy of the Macula trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Galimedix Therapeutics pipeline card: 1 registered trials from official public datasets.Report a data error.